However, higher mazdutide doses (9-10 mg) show 20-21% weight loss at 20 weeks, suggesting that dose-escalation may equalize efficacy
doi:10.1038/s41398-019-0515-5 Paddon-Jones D, Westman E, Mattes RD, Wolfe RR, Astrup A, Westerterp-Plantenga M
If retatrutide is licensed in due course, switching can be considered then, on evidence rather than anticipation
Other situations requiring prompt communication with your provider include persistent nausea or vomiting lasting more than 24-48 hours, signs of dehydration (decreased urination, dizziness, dry mouth), visual changes, symptoms of hypoglycemia (shakiness, confusion, rapid heartbeat), or unexplained neck mass or hoarseness
Licensed, NICE-appraised alternatives for eligible adults include semaglutide (Wegovy, TA875) and tirzepatide (Mounjaro, TA1026), available via NHS pathways